FRI487 Oral Liquid L- Thyroxine (L-T4) Is More Effective In Controlling Hypothyroidism, Than L-T4 Tablet, In Patients Submitted To Total Thyroidectomy

Disclosure: P. Fallahi: None. S. Ferrari: None. F. Ragusa: None. G. Elia: None. G. Materazzi: None. S. Paparo: None. A. Patrizio: None. V. Mazzi: None. P. Miccoli: None. A. Antonelli: None. Objectives: Our aim is to investigate the efficacy of levothyroxine (L-T4) in liquid formulation in patients recently subjected to total thyroidectomy (without malabsorption or drug interference), with respect to L-T4 tablets. Methods: We enrolled two hundred and twenty-five patients of whom 75 received L-T4 in tablets, and 150 were treated with liquid L-T4 at the same dosage (1.5 mcg/kg/day). The therapy started the day after thyroidectomy, and the drugs were assumed every day 30 min before breakfast. The thyroid profile was assessed by evaluating serum thyrotropic hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) in a first control after 6 weeks, then in a second control after 12 weeks. Results: Our results showed that the prevalence of patients in the hypothyroid range (TSH>3.6 mcU/ml) was significantly higher in the L-T4 tablet group. Moreover, TSH values were significantly lower in the liquid L-T4 group, than in the tablet L-T4 group both at the first (P < 0.05), and at the second control (P < 0.01), while FT4 and FT3 levels were not significantly different. Conclusions: Our data showes that thyroidectomized patients, not reporting issues of malabsorption, gastric disorders, or drug interference, have a better control of TSH levels under a liquid L-T4 therapy. Presentation: Friday, June 16, 2023